Ferinject Approved in China for the Treatment of Iron Deficiency in Adult Patients

Published on: 

NMPA has approved Ferinject in China for the treatment of iron deficiency or iron deficiency anemia.

CSL Vifor and Fresenius Kabi announced on Nov. 28. 2022 that China’s National Medical Products Administration (NMPA) has approved Ferinject (ferric carboxymaltose), a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective or cannot be used. Ferinject has now received marketing authorization in 85 countries worldwide.

According to a company press release, China has the world’s largest iron deficiency anemia population, with an estimated prevalence of 15%. The treatment’s approval is intended to benefit the Chinese healthcare system, among others, through implementation of a more effective patient blood management. The launch of Ferinject is expected in the first half of 2023.

“We are thrilled about the marketing authorization of Ferinject, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia,” said Hervé Gisserot, general manager of CSL Vifor, in the release. “There is a high unmet need in China, which has the world’s largest iron deficiency population, and we are confident that Ferinject can make a meaningful difference in the treatment of these patients. At the same time, this is another important step in our goal to globalizing and maximizing the performance of our iron franchise as we look forward to bring this treatment to market as soon as possible.”


Source: CSL Vifor